Readout LOUD podcast: NIH uncertainty thwarts U.S. researchers

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

How has the National Institutes of Health been spending its budget? Why are biotech investors feeling gloomy? And what is the most quintessential Boston movie?

We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We bring on STAT reporter Anil Oza and Heather Pierce, senior director of science policy at the Association of American Medical Colleges, to discuss the how the NIH distributed its money in the latest funding cycle and the effects on U.S. biomedical research.

We also chat about the shuttering of a CRISPR CAR-T biotech, the Nobel Prize in medicine, and biotech investors’ current mood.

For more on the NIH, go here; to learn more about the closing of the CAR-T company, go here; and for more on Nobel Prize, go here.

Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, or wherever you get your podcasts.